Search

Author/Creator Vavro, Cindy

1. Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study. Issue 3 (April 2015)

Authors:
Akil, Bisher; Blick, Gary; Hagins, Debbie P; Ramgopal, Moti N; Richmond, Gary J; Samuel, Rafik M; Givens, Naomi; Vavro, Cindy; Song, Ivy H; Wynne, Brian; Ait-Khaled, Mounir
Journal:
Antiviral therapy
Issue:
Volume 20:Issue 3(2015)
Page Start:
343
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Issue 12 (December 2017)

Authors:
Orrell, Catherine; Hagins, Debbie P; Belonosova, Elena; Porteiro, Norma; Walmsley, Sharon; Falcó, Vicenç; Man, Choy Y; Aylott, Alicia; Buchanan, Ann M; Wynne, Brian; Vavro, Cindy; Aboud, Michael; Smith, Kimberly Y
Journal:
Lancet
Issue:
Volume 4:Issue 12(2017)
Page Start:
e536
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. (5th April 2019)

Authors:
Viani, Rolando M; Ruel, Theodore; Alvero, Carmelita; Fenton, Terry; Acosta, Edward P; Hazra, Rohan; Townley, Ellen; Palumbo, Paul; Buchanan, Ann M; Vavro, Cindy; Singh, Rajendra; Graham, Bobbie; Anthony, Patricia; George, Kathleen; Wiznia, Andrew
Journal:
Journal of the Pediatric Infectious Diseases Society
Issue:
Volume 9:Number 2(2020)
Page Start:
159
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗